BioCentury | Nov 7, 2020
Targets & Mechanisms

Product profiles that could make interferons effective against COVID-19

The recent failure of IFNβ in WHO’s master protocol trial for COVID-19 notwithstanding, there are plenty of reasons to suspect that interferons should be effective treatments for the infection. An analysis...
BioCentury | Aug 6, 2020
Emerging Company Profile

Off-the-shelf cell therapy pioneers, Versant launch Matterhorn to tackle broad range of cancers

Versant’s Ridgeline incubator in Basel has launched Matterhorn with an off-the-shelf MR1T cell therapy designed to address a broader range of cancers than CAR T and TCR therapies. The company raised a $30 million series...
BioCentury | May 6, 2020
Politics, Policy & Law

Bright shines harsh light on America’s COVID-19 preparedness, FDA’s independence

...drop everything and make the chloroquine donated by Bayer widely available to the American public. Mr... Aeolus Pharmaceuticals Inc. (OTCQX:AOLS). “In attempting to justify the extension of this failed contract, Mr...
BioCentury | Apr 25, 2020
Management Tracks

COVID-19 takes life of former FDA Commissioner Kennedy

...editorial noting Kennedy’s departure from FDA, The New York Times wrote presciently that “several of Mr...
BioCentury | Mar 3, 2020
Politics, Policy & Law

Pricing speed bump for COVID-19 funding; Trump administration sending mixed messages on pricing, funding

...DNA vaccine by year-end, Kim said, “but to scale beyond that, we need your help, Mr...
BioCentury | Jan 25, 2020
Preclinical News

Ervaxx pursues non-peptide tumor antigens via Cardiff University TCR, T cell deal

A research collaboration with Cardiff University will enable Ervaxx to go beyond targeting neoantigens derived from typically unexpressed DNA, to tumor antigens that aren’t peptides. Ervaxx Ltd. will fund research, conducted in the lab of...
BioCentury | Sep 17, 2019
Company News

Couple charged with stealing secrets to form Chinese, U.S. biotech companies

...Chen. It added that the “business resulting from the transaction in which Avalon GloboCare acquired Mr...
BioCentury | Aug 28, 2019
Company News

Aug. 28 Company Quick Takes: Amgen to appeal Repatha ruling and EcoR1 buys Woodford’s stake in Prothena; plus DarwinHealth-Celgene, CRISPR IP, Trevena and Shink

...for brain injury candidate FDA accepted an IND from Shinkei Therapeutics Inc. (Princeton, N.J.) for MR-301...
...Corp. DarwinHealth EcoR1 Capital Prothena Corp. plc Regeneron Pharmaceuticals Inc. Sanofi Trevena Inc. University of California Woodford Investment Management Proprotein convertase subtilisin/kexin type 9 (PCSK9) CRISPR MR-301 Shinkei...
BioCentury | Apr 29, 2019
Clinical News

April 29 Quick Takes: Faron, Orchard

Faron's Traumakine fails Japanese Phase III for ARDS Faron Pharmaceuticals Oy (LSE:FARN) said partner Maruishi Pharmaceutical Co. Ltd. (Osaka, Japan) reported that Traumakine missed the primary endpoint in a Japanese Phase III trial to treat...
BioCentury | Jan 15, 2019
Distillery Techniques

Drug platforms Dec. 11, 2018 doi:10.1016/j.celrep.2018.11.067 CONTACT: Michael G. Rossmann, Purdue University, West Lafayette, Ind. email: Jennie...
Items per page:
1 - 10 of 281